Floatz logo

TRASTUZUMAB

Urinary Bladder Neoplasm

Cancer Research UKmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Urinary Bladder Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB
Nivolumab
Ikena Oncology
Phase 2B

View all 37 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →